Freelance cannabis brand consultant Saxon Wyatt says Australia is on the precipice of a booming cannabis industry – if we can get it right. 

Despite the snail-pace movement, it’s still a dizzying time in the Australian cannabis industry right now what with the TGA’s recent decision that could see CBD available over the pharmacy counter by mid-2021 and state-based industrial hemp harvests flourishing across the country.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Plus we’ve seen demand for medicinal cannabis boom with prescriptions up by 82% in 2020 according to TGA figures and ASX biotechs and pharmaceuticals leading the growth of medicinal cannabis on a local and global scale.

While this is all great local news, it poses the question: will the Australian cannabis industry catch up to North America’s sophisticated market? One that sees micro-growers and biotechs shape a thriving recreational and medicinal cannabis market predicted to be worth US$35 billion by 2024.

Back home, even with the ODC and TGA helping to move the industry in the right direction, the every-state-for-itself attitude is making national reform a little hazy. A case in point was the Greens’ efforts to make medicinal cannabis use a defence against drug-driving convictions being voted down in the NSW parliament.

It feels like only the likes of big pharma will stand a chance of cracking through the regulatory fog. 

The long-term danger for Australian cannabis consumers is a sea of sameness – a homogenised and limited product range offered by a handful of biotechs and only available through compound chemists with no point of product difference.